Search

Your search keyword '"Nieuwenhuizen, W. F."' showing total 2 results
Start Over Author "Nieuwenhuizen, W. F." Topic cholesterol
2 results on '"Nieuwenhuizen, W. F."'

1. The effect of dietary phytosphingosine on cholesterol levels and insulin sensitivity in subjects with the metabolic syndrome.

Author

Snel M, Sleddering MA, Pijl H, Nieuwenhuizen WF, Frölich M, Havekes LM, Romijn JA, and Jazet IM

Subjects
Cholesterol, LDL blood, Cross-Over Studies, Dietary Supplements, Double-Blind Method, Glucose Tolerance Test, Humans, Insulin blood, Male, Metabolic Syndrome blood, Middle Aged, Triglycerides blood, Blood Glucose metabolism, Cholesterol blood, Dietary Fats administration & dosage, Insulin Resistance, Metabolic Syndrome drug therapy, Sphingolipids pharmacology, Sphingosine pharmacology
Abstract

Background: Sphingolipids, like phytosphingosine (PS) are part of cellular membranes of yeasts, vegetables and fruits. Addition of PS to the diet decreases serum cholesterol and free fatty acid (FFA) levels in rodents and improves insulin sensitivity., Objective: To study the effect of dietary supplementation with PS on cholesterol and glucose metabolism in humans., Methods: Twelve men with the metabolic syndrome (MetS) (according to the International Diabetes Federation (IDF) criteria; age 51+/-2 years (mean+/-s.e.m.); body mass index (BMI) 32+/-1 kg/m(2)) were randomly assigned to 4 weeks of PS (500 mg twice daily) and 4 weeks of placebo (P) in a double-blind cross-over study, with a 4-week wash-out period between both interventions. At the end of each intervention anthropometric measures and serum lipids were measured and an intravenous glucose tolerance test (IVGTT) was performed., Results: Phytosphingosine did not affect body weight and fat mass compared with P. PS decreased serum total cholesterol (5.1+/-0.3 (PS) vs 5.4+/-0.3 (P) mmol/l; P<0.05) and low-density lipoprotein (LDL)-cholesterol levels (3.1+/-0.3 (PS) vs 3.4+/-0.3 (P) mmol/l; P<0.05), whereas it did not alter serum triglyceride and high-density lipoprotein (HDL)-cholesterol levels. In addition, PS lowered fasting plasma glucose levels (6.2+/-0.3 (PS) vs 6.5+/-0.3 (P) mmol/l; P<0.05). PS increased the glucose disappearance rate (K-value) by 9.9% during the IVGTT (0.91+/-0.06 (PS) vs 0.82+/-0.05 (P) %/min; P<0.05) at similar insulin levels, compared with P, thus implying enhanced insulin sensitivity. PS induced only minor gastrointestinal side effects., Conclusion: Dietary supplementation of PS decreases plasma cholesterol levels and enhances insulin sensitivity in men with the MetS.

Published
2010
Full Text
View/download PDF

2. Dietary sphingolipids lower plasma cholesterol and triacylglycerol and prevent liver steatosis in APOE*3Leiden mice

Author

Duivenvoorden, I., Voshol, P. J., Patrick Rensen, Duyvenvoorde, W., Romijn, J. A., Emeis, J. J., Havekes, L. M., Nieuwenhuizen, W. F., and TNO Kwaliteit van Leven

Subjects
Steatosis, cholesterol blood level, Apolipoprotein E3, Gene Expression, Fatty Acids, Nonesterified, Lipoproteins, VLDL, Cholesterol, Dietary, Feces, Mice, Random Allocation, dose response, lipid metabolism, hepatitis, animal, genetics, plasma clearance, apolipoprotein E, messenger RNA, drug effect, article, amyloid, very low density lipoprotein, Cholesterol, female, nutritional assessment, Liver, diet supplementation, cholesterol ester, lipids (amino acids, peptides, and proteins), prophylaxis, triacylglycerol, Health Biology, alanine aminotransferase, enzymology, Lipolysis, APOE*3Leiden mice, animal experiment, Mice, Transgenic, randomization, Free fatty acids, chemistry, Food technology, animal tissue, Apolipoproteins E, blood, Animals, controlled study, lipogenesis, mouse, Triglycerides, phytosphingosine, fatty liver, Sphingolipids, nonhuman, cholesterol intake, Dose-Response Relationship, Drug, animal model, intestine absorption, transgenic mouse, drug structure, Intestinal Absorption, physiology, apolipoprotein E3 (Leidein), cholesterol metabolism, RNA, fatty acid, sphingolipid, metabolism
Abstract

Background: The prevalence of dyslipidemia and obesity resulting from excess energy intake and physical inactivity is increasing. The liver plays a pivotal role in systemic lipid homeostasis. Effective, natural dietary interventions that lower plasma lipids and promote liver health are needed. Objective: Our goal was to determine the effect of dietary sphingolipids on plasma lipids and liver steatosis. Design: APOE*3Leiden mice were fed a Western-type diet supplemented with different sphingolipids. Body cholesterol and triacylglycerol metabolism as well as hepatic lipid concentrations and lipid-related gene expression were determined. Results: Dietary sphingolipids dose-dependently lowered both plasma cholesterol and triacylglycerol in APOE*3Leiden mice; 1% phytosphingosine (PS) reduced plasma cholesterol and triacylglycerol by 57% and 58%, respectively. PS decreased the absorption of dietary cholesterol and free fatty acids by 50% and 40%, respectively, whereas intestinal triacylglycerol lipolysis was not affected. PS increased hepatic VLDL-triacylglycerol production by 20%, whereas plasma lipolysis was not affected. PS increased the hepatic uptake of VLDL remnants by 60%. Hepatic messenger RNA concentrations indicated enhanced hepatic lipid synthesis and VLDL and LDL uptake. The net result of these changes was a strong decrease in plasma cholesterol and triacylglycerol. The livers of 1% PS-fed mice were less pale, 22% lighter, and contained 61% less cholesteryl ester and 56% less triacylglycerol than livers of control mice. Furthermore, markers of liver inflammation (serum amyloid A) and liver damage (alanine aminotransferase) decreased by 74% and 79%, respectively, in PS-fed mice. Conclusion: Sphingolipids lower plasma cholesterol and triacylglycerol and protect the liver from fat- and cholesterol-induced steatosis. © 2006 American Society for Nutrition.Chemicals / CAS: alanine aminotransferase, 9000-86-6, 9014-30-6; amyloid, 11061-24-8; cholesterol, 57-88-5; phytosphingosine, 13552-11-9, 554-62-1; RNA, 63231-63-0; apolipoprotein E3 (Leidein); Apolipoprotein E3; Apolipoproteins E; Cholesterol, 57-88-5; Cholesterol, Dietary; Fatty Acids, Nonesterified; Lipoproteins, VLDL; RNA, 63231-63-0; Sphingolipids; Triglycerides

Catalog

Books, media, physical & digital resources
See catalog results